Sex dimorphism and cancer immunotherapy: may pregnancy solve the puzzle?
In the last decade, growing interest has emerged about sex dimorphism of immune response in the context of anti-cancer immunotherapy. Specifically, sex includes physiological and anatomical variables such as chromosome asset and organization, reproductive organs and sex hormones levels which can ultimately affect the pathogenesis of several diseases, including cancer [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 27, 2023 Category: Cancer & Oncology Authors: Francesco Maria Venanzi, Marta Bini, Antonio Nuccio, Alessandro De Toma, Matteo Lambertini, Francesca Rita Ogliari, Sara Oresti, Maria Grazia Vigan ò, Elena Brioschi, Maggie Polignano, Matteo Maria Naldini, Silvia Riva, Michele Ferrara, Nicola Fogale, Gi Tags: Anti-tumour Treatment Source Type: research
Malignant ascites: current therapy options and treatment prospects
Ascites is defined as the accumulation of serous fluid in the peritoneal cavity and can be caused by various underlying diseases. Based on cytologic criteria three subtypes of ascites can be distinguished. Benign ascites most likely occurs in patients with liver cirrhosis or heart insufficiency without the presence of a malignant disease or tumor cells within the ascitic fluid. Malignant ascites (MA) is defined as cytologic proof of tumor cells within the ascitic fluid. However, a third entity called paramalignant ascites has been described recently, defined as the presence of ascites in cancer patients without detectable ...
Source: Cancer Treatment Reviews - October 23, 2023 Category: Cancer & Oncology Authors: Julia M. Berger, Matthias Preusser, Anna S. Berghoff, Elisabeth S. Bergen Tags: Anti-tumour Treatment Source Type: research
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy
AGO-B WSG PreCycle (NCT03220178) was a multicenter, randomized, parallel-group, phase IV clinical trial designed to evaluate the impact of electronic Patient-Reported Outcome (ePRO) support in advanced and metastatic breast cancer (MBC) using CANKADO [1] CANKADO is a next-generation interactive autonomous patient empowerment application that requires no intervention by a healthcare professional (HCP) and can self-detect points in time to initiate symptom questionnaires. Patients are queried daily about their general health; the response is entered via a user-friendly smiley slider, graphically based on the EQ-VAS. (Source:...
Source: Cancer Treatment Reviews - October 18, 2023 Category: Cancer & Oncology Authors: Nadia Harbeck, Ronald Kates, Timo Schink öthe, Johannes Schumacher, Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, Philip Räth, Oliver Hoffmann, Ralf Lorenz, Thomas Decker, Mattea Reinisch, Thomas Göhler, Peter Staib, Oleg Gluz, Peter A Fasching, M Tags: Anti-tumour Treatment Source Type: research
Evolution of the HIF Targeted Therapy in Clear Cell Renal Cell Carcinoma
Renal cell carcinoma (RCC) represents the sixth most commonly diagnosed cancer in men and the 10th in women, with approximately 81,800 new cases diagnosed, and over 14,000 deaths in 2023 in the United States.[1,2] Incidence of kidney cancer increases with age, and most cases are diagnosed in individuals aged 70 years or older. Smoking, obesity, and hypertension are among modifiable risk factors for development of this disease.[3] (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 15, 2023 Category: Cancer & Oncology Authors: Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega Tags: Anti-tumour Treatment Source Type: research
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
Activating mutations of the gene encoding the estrogen receptor (ER) alpha (ESR1) are among the most common mechanisms of endocrine therapy (ET) resistance in patients with hormone receptor (HR)+/HER2- breast cancer (BC) [1,2]. These acquired events have been reported in ∼ 40% of metastatic BC (MBC) progressed on an aromatase inhibitor (AI) treatment, and can be detected on cell-free circulating DNA (cfDNA) [3]. Currently, there are more than 60 identified ESR1 mutation variants, mainly found in the ligand-binding domain (LBD) of ER, leading to ligand-independe nt activation of the receptor. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 12, 2023 Category: Cancer & Oncology Authors: Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone, Elena Guerini Rocco, Giuseppe Curigliano, Nicola Fusco, Umberto Mal Tags: Anti-tumour Treatment Source Type: research
ESR1 mutations in HR+/HER2- metastatic breast cancer: enhancing the accuracy of ctDNA testing
Activating mutations of the gene encoding the estrogen receptor (ER) alpha (ESR1) are among the most common mechanisms of endocrine therapy (ET) resistance in patients with hormone receptor (HR)+/HER2- breast cancer (BC) [1,2]. These acquired events have been reported in ∼40% of metastatic BC (MBC) progressed on an aromatase inhibitor (AI) treatment, and can be detected on cell-free circulating DNA (cfDNA) [3]. Currently, there are more than 60 identified ESR1 mutation variants, mainly found in the ligand-binding domain (LBD) of ER, leading to ligand-independent a ctivation of the receptor. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 12, 2023 Category: Cancer & Oncology Authors: Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone, Elena Guerini Rocco, Giuseppe Curigliano, Nicola Fusco, Umberto Mal Tags: Anti-tumour Treatment Source Type: research
The prognostic potential of CDX2 in colorectal cancer: harmonizing biology and clinical practice
According to the Global Cancer Observatory, colorectal cancer (CRC) is the third-most common cancer type and the second-most cancer-related cause of death worldwide. Clinical management of CRC is guided by the Tumor-Node-metastasis (TNM) AJCC/UICC classification [1 –3]. However, about 30% of CRC patients will experience disease relapse [4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 12, 2023 Category: Cancer & Oncology Authors: Jordi Badia-Ramentol, Francisco Gimeno-Valiente, Elena Dur éndez, Carolina Martínez-Ciarpaglini, Jenniffer Linares, Mar Iglesias, Andrés Cervantes, Alexandre Calon, Noelia Tarazona Tags: Anti-tumour Treatment Source Type: research
Revisiting the concept of Neoadjuvant and Induction Therapy in Head and Neck Cancer with the advent of Immunotherapy
With over 650,000 new diagnoses every year, Head and Neck Squamous Cell Carcinoma (HNSCC) is the fifth most common cancer worldwide, with increasing incidence in recent years. The majority of HNSCC is classified as locally advanced (LA) at diagnosis (more than 80%) based on TNM classification [1]. To date, treatment of LA HNSCC is based on surgery plus radiation in combination or not with chemotherapy or definitive (chemo)radiation, depending on site and stage [2]. Despite optimal locoregional treatment, 50% of patients recur, with a huge impact on prognosis: in fact, 5-year overall survival (OS) for LA HNSCC is reported t...
Source: Cancer Treatment Reviews - October 12, 2023 Category: Cancer & Oncology Authors: Davide Smussi, Davide Mattavelli, Alberto Paderno, Cristina Gurizzan, Luigi Lorini, Chiara Romani, Eliana Bignotti, Alberto Grammatica, Marco Ravanelli, Paolo Bossi Tags: Anti-tumour Treatment Source Type: research
Editorial Board
(Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 10, 2023 Category: Cancer & Oncology Source Type: research
AXL – a new player in resistance to HER2 blockade
HER2 (gene name, ERBB2) transmembrane glycoprotein receptor is a member of the human epidermal growth factor receptor (HER) family together with receptors HER1, HER3, and HER4. Homo- or hetero-dimerization of these receptors activate key downstream pathways, being HER2-HER3 the most prevalent and potent heterodimer in signaling [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 7, 2023 Category: Cancer & Oncology Authors: Anna Adam-Artigues, Enrique J. Arenas, Joaqu ín Arribas, Aleix Prat, Juan Miguel Cejalvo Tags: Anti-tumour Treatment Source Type: research
AXL- a new player in resistance to HER2 blockade
HER2 (gene name, ERBB2) transmembrane glycoprotein receptor is a member of the human epidermal growth factor receptor (HER) family together with receptors HER1, HER3, and HER4. Homo- or hetero-dimerization of these receptors activate key downstream pathways, being HER2-HER3 the most prevalent and potent heterodimer in signaling [1]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 7, 2023 Category: Cancer & Oncology Authors: Anna Adam-Artigues, Enrique J. Arenas, Joaqu ín Arribas, Aleix Prat, Juan Miguel Cejalvo Tags: Anti-tumour Treatment Source Type: research
Engineering strategies to optimise adoptive cell therapy in ovarian cancer
Advanced ovarian cancer has traditionally been associated with a poor prognosis with 5-year survival rates of approximately 30%. Recent advances in targeted therapies, specifically poly (ADP-ribose) polymerase inhibitors (PARPi), have significantly improved the prognosis for some patients, however, treatments are limited to biomarker defined subgroups. New treatments for the remainder, and for those who fail targeted therapy, are urgently required. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - October 4, 2023 Category: Cancer & Oncology Authors: Catarina Guerra, Milena Kalaitsidou, Gray Kueberuwa, Robert Hawkins, Richard Edmondson Tags: Anti-tumour Treatment Source Type: research
Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer
Integrated multidisciplinary care (MDC) is essential for the optimized management of patients with prostate cancer (PCa) due to the complexity of the disease and increasing availability of novel diagnostic and therapeutic options with novel mechanisms of action [1,2]. MDC enables dynamic discussions about key diagnostic steps, pre-treatment risk classification, and therapeutic options [3,4]. Other benefits include training opportunities for healthcare professionals (HCPs), lowering physician bias, increased patient engagement, promoting racial equity, and improving shared decision-making [5-8]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 26, 2023 Category: Cancer & Oncology Authors: Jason A. Efstathiou, Alicia K. Morgans, Christopher Bland, Neal D. Shore Tags: Anti-tumour Treatment Source Type: research
Regulatory T cells in gastric cancer: key controllers from pathogenesis to therapy
Gastric cancer (GC) is a highly aggressive malignant disease responsible for over 700,000 deaths worldwide annually [1]. In 2020 alone, there were approximately 1.1 million new cases of GC, making it the fifth most common malignancy and the fourth leading cause of cancer-related death globally [2]. Asian countries, including Japan, Mongolia, and the Republic of Korea, exhibit a significantly higher incidence and prevalence of GC compared to Western countries [3]. Early-stage GC is often asymptomatic, necessitating screening upper gastrointestinal (GI) endoscopy with biopsy as the primary method for reliable diagnosis. (Sou...
Source: Cancer Treatment Reviews - September 23, 2023 Category: Cancer & Oncology Authors: Ion Negura, Mariana Pavel-Tanasa, Mihai Danciu Tags: Tumour Review Source Type: research
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
The epidermal growth factor receptor (EGFR) is a transmembrane protein that influences the pathogenesis in a subset of non-small cell lung cancers (NSCLC) [1]. Activation of EGFR is achieved by somatic mutations that lead to a ligand-independent activation of EGFR and uncontrolled cell growth [2,3]. Over the past decades, multiple tyrosine kinase inhibitors (TKIs) have been developed to inhibit growth of EGFR-mutated NSCLC. These drugs affect the intrinsic mitochondrial apoptotic pathway and thereby induce cell death [4]. (Source: Cancer Treatment Reviews)
Source: Cancer Treatment Reviews - September 19, 2023 Category: Cancer & Oncology Authors: Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken Tags: Anti-tumour Treatment Source Type: research
